F tier · safety concern
Prostamax has a fully verified structure but not one human clinical outcome study of any design: its six PubMed-indexed papers are chromatin and calorimetry experiments on cells, and ClinicalTrials.gov returns zero registered studies — while the clinical results the market attributes to it actually belong to Prostatilen, a different prostate preparation.
prostamax
Prostamax is the prostate-directed member of the Khavinson series and, unusually for the family, is unambiguously identified: PubChem lists it by name as Lys-Glu-Asp-Pro with a CAS number. Its published work is confined to chromatin decondensation and microcalorimetry in cultured human lymphocytes, plus one organotypic tissue-culture screen. There is no clinical trial, no human outcome study, and no prostate-tissue functional experiment in the retrievable literature.
// we supply this one
available as a research reagent
≥ 98% HPLC · lyophilised powder · batch certificate published. Grade F above is our own and is not adjusted because we stock it.
the explanation
Prostamax is a four-amino-acid peptide sold as a prostate peptide. We can confirm exactly what it is, which is more than can be said for most of this family. What cannot be confirmed is that it does anything: the handful of published experiments look at how it loosens up chromatin in white blood cells in a dish. There has never been a clinical trial, and the prostate results people cite belong to a different Russian product called Prostatilen.
regulatory status
No medicinal approval anywhere; unlicensed in the UK; research reagent only
Prostamax holds no marketing authorisation as a medicine in the UK, EU or US, and no MHRA, EMA or FDA assessment exists. A ClinicalTrials.gov query returns zero registered studies of Prostamax. It should not be confused with Prostatilen, a prostate-extract preparation registered in Russia for which Khavinson's group does report clinical results; Prostamax itself is absent from that clinical review. It is not named on the WADA Prohibited List. In the UK it is not a licensed medicine, not a prescription-only medicine, not a controlled drug and not an authorised supplement ingredient; lawful supply is as a laboratory reagent not for human consumption.
how it works · proposed mechanism
The proposed mechanism is epigenetic: the peptide enters the nucleus and reverses age-related condensation of chromatin, releasing genes silenced by heterochromatinisation. Nearly all of the supporting work is cytogenetic and was performed on lymphocytes rather than prostate tissue. Tissue specificity for the prostate is asserted rather than shown.
Chromatin decondensation in aged lymphocytes
In leukocytes from subjects aged 75-88, Prostamax alongside Vilon, Epithalon, Livagen and Cortagen was reported to activate ribosomal genes and decondense densely packed chromatin, with Prostamax among the peptides affecting chromosome 1 pericentromeric structural heterochromatin. This is an ex vivo cytogenetic readout on blood cells, not a prostate outcome.
Deheterochromatinisation attributed to KEDP
A Tbilisi group reported deheterochromatinisation of chromatin in old age induced by the oligopeptide bioregulator Lys-Glu-Asp-Pro, and separately used microcalorimetry to study lymphocyte cultures exposed to prostamax with copper and cadmium. These authors are long-standing Khavinson collaborators rather than an independent check, and the endpoints are thermodynamic and cytogenetic.
Tissue specificity asserted from a screen
One organotypic culture study grouped Prostamax with Cardiogen, Bronchogen and Pancragen and reported stimulation in matching tissues. It is a low-resolution screen across several peptides and tissues, and does not demonstrate a prostate-specific molecular pathway.
No prostate physiology anywhere in the record
The retrievable literature contains no measurement of prostate volume, glandular histology, androgen signalling, inflammatory markers or urinary function following Prostamax. The prostate designation rests on the organ from which the parent peptide complex was originally derived, not on demonstrated organ-level effect.
what’s reported
evidence shape
7 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Prostamax is a well-identified molecule with no prostate evidence. Its chemistry checks out precisely — PubChem lists it under its own name as Lys-Glu-Asp-Pro, C20H33N5O9, 487.5, CAS 473578-47-1 — but all six PubMed-indexed papers are cytogenetics and calorimetry on cultured or donor-derived lymphocytes, and not one measures anything about the prostate. ClinicalTrials.gov holds zero registered studies. The clinical claims circulating in the market for a Khavinson prostate peptide belong to Prostatilen, a registered Russian prostate-extract product that features in the group's 2014 review of clinical results; Prostamax does not appear in that review at all. The nominally separate Tbilisi laboratory that produced most of the chromatin work has co-published with Khavinson, so it is not an independent replication either.
key published findings
- ClinicalTrials.gov contains zero registered studies of Prostamax (verified by registry query).
- Chemistry fully verified against PubChem: named record CID 9848296, Lys-Glu-Asp-Pro confirmed by the deposited structure, C20H33N5O9, 487.5, CAS 473578-47-1.
- Only six PubMed-indexed publications name prostamax, and every one is a cell-level cytogenetic or calorimetric experiment; none measures a prostate endpoint and none is a clinical trial.
- The clinical results attributed in the market to a Khavinson prostate peptide belong to Prostatilen, a different registered prostate-extract preparation; Prostamax is absent from the group's own 2014 clinical-results review.
- The Tbilisi chromatin group that authored most of the prostamax papers has co-published with Khavinson, so their work is a collaboration rather than independent replication.
- The main human-cell study used leukocytes from donors aged 75-88 and tested five peptides together, so effects are neither prostamax-specific nor patient outcomes.
limitations of the evidence
- Zero human clinical studies of any design, controlled or otherwise, and zero registered trials.
- No experiment in the retrievable literature measures prostate tissue, prostate function or any urological outcome.
- The organ designation derives from the source tissue of the original peptide complex, not from demonstrated tissue specificity in the prostate.
- Key papers are in Biofizika and Georgian Medical News, low-indexing venues, and the authoring laboratory is a long-term Khavinson collaborator rather than an independent group.
- Market claims routinely borrow Prostatilen's clinical record, a materially different preparation, which is the single most misleading feature of how this compound is sold.
- Sources overlap with the other Khavinson bioregulators in this index because these compounds are described in one shared body of literature; shared reviews and screens are not independent support for prostamax.
documented safety signals
- No toxicology package, no human safety study and no adverse-event surveillance were located for Prostamax.
- Absence of reported harm reflects absence of monitored human exposure rather than demonstrated safety.
- The claimed mechanism is de-repression of age-condensed chromatin and activation of ribosomal genes; the oncological implications of that in prostate tissue have never been examined, which is a notable gap for a compound aimed at an organ with high latent carcinoma prevalence.
identity
| full name | Prostamax (Lys-Glu-Asp-Pro; KEDP tetrapeptide) |
| category | Other |
| modality | peptide |
| formula | C20H33N5O9 |
| molar mass | 487.5 g/mol |
| cas | 473578-47-1 |
| sequence | Lys-Glu-Asp-Pro (KEDP) |
laboratory handling
| storage | Lyophilised powder is stored desiccated at -20 °C and protected from light. Once reconstituted, laboratory practice is refrigeration at 2-8 °C for short-term use, or aliquoting and freezing to avoid repeated freeze-thaw cycles. Handling information only; this material has no approved human use. |
| solubility | Short hydrophilic peptide, readily soluble in sterile or bacteriostatic water and in dilute aqueous buffer. Lot-specific solubility is stated on the certificate of analysis. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
7 citedPubChem, NCBI · 2026 · official
ClinicalTrials.gov, US National Library of Medicine · 2026 · official
Advances in Gerontology · 2014 · review
Bulletin of Experimental Biology and Medicine · 2004 · preclinical
Georgian Medical News · 2012 · preclinical
Georgian Medical News · 2009 · preclinical
Advances in Gerontology · 2006 · preclinical
others in Other